Whiteoak Capital Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹500

Whiteoak Capital Pharma & Healthcare Growth Direct Plan

NAV
₹13.8040
+0.55%
(16 Jun)
AUM
332 Cr
TER
0.68%
Risk
Very High Risk
Insights
Asset Under Management (AUM) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+28.7%
+5.6%
+0.8%
-1.5%
-2.4%
3Y
NA
+36.3%
+35.9%
+37.7%
+38.7%
5Y
NA
+32.8%
+36.8%
+32.6%
+31.5%
ALL
+26.5%
+18.3%
+13.2%
+12.2%
+17.4%
VOL
15.7%
16.4%
21.2%
20.4%
19.9%
TER
0.7%
0.5%
1.0%
0.8%
0.9%
AUM
₹332 Cr
₹6,864 Cr
₹2,540 Cr
₹5,259 Cr
₹1,394 Cr
INFO
1.68
1.12
0.62
0.60
0.87
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Whiteoak Capital Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Apr
Top holdings
Sun Pharmaceuticals Industries Ltd
11.3%
Cipla Ltd
7.6%
Divi's Laboratories Ltd
7.4%
Max Healthcare Institute Ltd Ordinary Shares
7.2%
Lupin Ltd
5.4%
Torrent Pharmaceuticals Ltd
4.0%
Laurus Labs Ltd
3.8%
Krishna Institute of Medical Sciences Ltd
3.8%
Fortis Healthcare Ltd
3.5%
Ipca Laboratories Ltd
2.8%
Top industry exposure
Healthcare
89.2%
Basic Materials
3.6%
Financial Services
0.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹500
Additional lumpsum
₹500
Portfolio turnover
308%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Piyush Baranwal
Ramesh Mantri
Trupti Agrawal
Dheeresh Pathak
Ashish Agrawal

FAQs